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Other names: 12CC4; FLJ23741; hFKH1B; 
HSPC215; MGC12942; MGC88572; MGC9551; 
QRF1 (Glutamine-Rich Factor 1) 
Location: 3p14.1 
Local order: 3p telomere-3' FOXP1 5'-centromere. 




21 exons; the first 5 exons, the 5' part of exon 6 and the 
3' part of exon 21 are non-coding. 
Transcription 
628405 bps mRNA; transcribed in a centromeric to 
telomeric orientation. Alternative splicing; 4 named 




Note: Forkhead box P1 
Description 
The FOXP1 protein is 677-amino acid long and its 
molecular weight is 75317 Da. It contains two potential 
nucleic acid-binding motifs, including a forkhead 
(winged-helix) domain and C2H2 zinc finger domain. 
Other regions that may regulate transcription and 
mediate protein-protein interaction include coiled-coil, 
glutamine rich, S/T-rich, S/T/P-rich and acidic rich 
domains. Two potential nuclear localization signals 
(NLS) were identified at amino acid 434-440 and 
amino acid 543-546. Two potential PEST motifs are 
predicted in the acidic region near its COOH terminus. 
The FOXP1 protein contains a number potential of 
cyclin-cdk phosphorylation sites and a recognition site 
for the p70S6-kinase which is itself regulated by the
PI(3)K. The FOXP1 protein forms homodimers and 
heterodimers with FOXP2 and FOXP4. Dimerization is 
required for DNA-binding. 
 
(3p14.1): RP11-154H23 (Spectrum0range) and RP11-79P21 (SpectrumGreen) covering the 5' and the 3'end of FOXP1, respectively. 
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Schematic diagram of the Foxp1 protein indicating the localization of predicted domains and motifs. Modified from Banham AH et al., 
Cancer Res 61, 8820-8820, 2001. 
Expression 
Ubiquitous expression in normal adult and fetal human 
tissues; highest expression in lymphoid and 
gastrointestinal tissues. Within the B lineage, FOXP1 is 
expressed modestly in progenitors, with highest levels 




FOXP1 can act as a transcriptional repressor. The gen  
has a broad range of functions and plays an important 
role in cardiac and lung development, B-cell 
development and macrophage differentiation. FOXP1 
is implicated in malignancy. 
Homology 
Member of the broadly expressed FOXP subfamily 
which itself is a part of the FOX gene family of 
transcription factors, characterized by sharing a 
common DNA binding domain termed forkhead or a 
winged-helix domain. FOXP proteins (FOXP1, -2, -3, -
4) play important roles in immune responses, organ 
development and cancer pathogenesis. 
Implicated in 
 t(3;9)(p14;p13) → PAX5-FOXP1 in 
childhood ALL 
Disease 




Contains the NH2 terminus of PAX5 with the DNA-
binding paired, octapeptide and homeodomain-like  
domains and the COOH-terminus of FOXP1 containing 
its DNA-binding (Zn and FH) and transcriptional 
regulatory domains. 
Oncogenesis 
The fusion protein is predicted to retain the ability to 
bind to PAX5 and FOXP1 transcriptional targets, but
no longer provide normal transcriptional regulatory 
functions of both genes. 
t(3;14)(p14;q32) /B-cell malignancies 
IGH -FOXP1 
Disease 
t(3;14)(p14;q32) resulting in upregulated expression of 
FOXP1, is a rare aberration in B-NHL. The 
translocation occurs recurrently in MALT-type of 
marginal zone B-cell lymphomas (MZBCL) and diffuse 
large B cell lymphoma (DLBCL). Single cases with 
variant FOXP1 translocations involving unknown non-
IG loci have been reported. 
Of note, a significant number of DLBCL (with a 
predominantly ABC-like phenotype) and extranodal 
MZBCL displayed a strong expression of FOXP1 
which is independent of genomic rearrangements of the 
FOXP1 locus. FOXP1-positivity was also found in 
numerous cases of cutaneous B-cell lymphomas and 
follicular lymphomas. 
Prognosis 
High expression of FOXP1 in DLBCL is associated 
with poor prognosis. Deregulation of FOXP1 in MALT 
lymphomas possibly leads to transformation to a more 
aggressive DLBCL. 
Cytogenetics 
t(3;14) was recorded as a sole aberration and as a part 
of complex karyotypes. In MALT lymphomas, 
translocations involving FOXP1, MALT1 and BCL10 
are mutually exclusive. 
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Hybrid/Mutated Gene 
No hybrid gene; 5' FOXP1 juxtaposed with 3' IGH 
enhancer. Molecular characteristics of FOXP1 variant 
translocations are unknown. 
Oncogenesis 
The occurrence of activated FOXP1 translocations in 
lymphoma indicates that FOXP1 functions as an 
oncogene. So far, mechanisms and molecular 
consequences of aberrant expression of FOXP1 in 
lymphomas not harboring 3p14/FOXP1 rearrangements 
are unknown. The preliminary data suggest that not the 
full-length protein, but smaller FOXP1 isoforms are 
atypically highly expressed in ABC-DLBCL cell lines. 




FOXP1 abnormalities (overexpression, mislocalization  
 
or loss of FOXP1) are observed in a wide variety of  
cancers, particularly of epithelial origin. 
FOXP1 located in the 3p region frequently deleted in 
multiple types of cancers is one of a few potential 
tumor suppressor genes. Genomic loss of FOXP1 
correlates with a decrease in FOXP1 mRNA and/or a 
decrease in FOXP1 protein levels in a significant 
number of analyzed lung cancers and head and neck 
cancers. In addition, an aberrant cytoplasmic 
localization of FOXP1 has been observed in a number 
of epithelial malignancies. Whether that aberrant 
localization may be a mechanism for inactivation of 
FOXP1 remains to be determined. So far, the direct 
evidence that FOXP1 functions as a tumor suppressor 
gene is limited. 
In contrast, increased nuclear expression of FOXP1 has 
been detected in renal cell carcinoma, some prostate 
cancers, endometrial cancers and breast cancers. The 
mechanisms leading to altered expression of FOXP1 in 
cancer are elusive. 
Breakpoints 
 
Recurrent (14q32/IGH) and non-recurrent chromosomal breakpoints/partners involved in the FOXP1 rearrangements in hematological 
malignancies. 
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